Brazil Halts Dengue Vaccine Use After Two Deaths

Brazil has halted the administration of the world's first single-dose dengue vaccine after two deaths were reported following vaccination. The vaccine, developed domestically and approved by health authorities in November, had been administered to over 500,000 people this year. This suspension raises concerns about the safety and efficacy of the groundbreaking inoculation against the mosquito-borne virus.

The dengue virus can cause severe symptoms including high fever, headaches, muscle pain, nausea, and rashes, and in rare instances, can be fatal. Of the 501,044 individuals who received the vaccine between January and May, a notable 3,703, or 0.7 percent, presented with symptoms similar to dengue. Additionally, the health ministry reported that 42 individuals experienced "more severe reactions" to the vaccine.

Investigations are underway into three severe cases, two of which resulted in fatalities: a 58-year-old man and a 48-year-old woman. A third patient, a 38-year-old woman, required intensive care but has since been discharged. The Brazilian health authorities are closely examining these incidents to determine any potential link between the vaccine and the adverse outcomes before deciding on the future of the vaccination program.